Four FDA Actions Reshaping Drug Development in 2026
• In early 2026, the FDA implemented four strategic actions to modernize drug development, shifting focus toward flexibility and human-centric science. • The agency is prioritizing evidence quality and analytical sophistication over the sheer volume of data, acknowledging that advances in genomic medicine and biomarkers have outpaced old frameworks. • A key regulatory change allows for drug approval based on a single adequate and well-controlled trial, provided it is supported by sufficient confirmatory evidence.
appliedclinicaltrialsonline.com